Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial

TRA 2(o)P-TIMI 50 Investigators, David A Morrow, Benjamin M Scirica, Keith A A Fox, Gail Berman, John Strony, Enrico Veltri, Marc P Bonaca, Polly Fish, Carolyn H McCabe, Eugene Braunwald

Research output: Contribution to journalArticlepeer-review

Abstract

Thrombin potently activates platelets via interaction with the protease-activated receptor 1. SCH 530348 is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin via antagonism of the protease-activated receptor 1. Because SCH 530348 does not interfere with other pathways for hemostasis, it is possible that SCH 530348 reduces thrombosis with less increase in bleeding than do other potent antiplatelet agents.
Original languageEnglish
Pages (from-to)335-341
Number of pages11
JournalAmerican Heart Journal
Volume158
Issue number3
DOIs
Publication statusPublished - Sep 2009

Fingerprint Dive into the research topics of 'Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial'. Together they form a unique fingerprint.

Cite this